

In the Claims:

This listing of claims will replace all prior versions, and listings, of claims in the application.

Upon entry of the present amendment, the claims will stand as follows:

Please cancel claims 3, and 9-12, without prejudice

Please amend claims 17, 19, 25, 29-32, 39, 40, 42, 45, 47 and 49 as follows:

Claims 1-16 (cancelled)

17. (Currently Amended) A method for enhancing collateral blood vessel formation in heart or limb muscle tissue, said method comprising:

directly injecting into a site of impaired blood flow in heart or limb muscle tissue an effective amount of early attaching cells obtained from autologous bone marrow, which early attaching cells have been transfected *in vitro* with an adenoviral vector comprising a polynucleotide encoding one or more angiogenic factors selected from hypoxia inducing factor-1 (HIF-1), endothelial PAS domain protein 1 (EPAS1), Monocyte Chemoattractant Protein 1 (MCP-1), granulocyte-monocyte colony stimulatory factor (GM-CSF), PR39, a fibroblast growth factor (FGF), and a nitric oxide synthase (NOS).

Claim 18 (Cancelled)

19. (Currently Amended) The method of claim 17, wherein the early attaching cells [[are]] consist essentially of marrow-derived stromal cells and the transfected cells are directly injected into a site of ischemia in the muscle tissue.

Claims 20-23 (Cancelled)

24. (Previously Presented) The method of claim 47, wherein the period of culturing is from about 3 hours to about 3 days.

25. (Currently Amended) The method of claim 17, further comprising filtering the bone marrow [prior to] and culturing [[of]] the bone marrow to obtain the early attaching cells.

Claims 26 – 28 (Cancelled)

29. (Currently Amended) The method of claim 17, wherein the [[agent]] angiogenic factor is selected from a fibroblast growth factor (FGF), a NOS, and PR39.

30. (Currently Amended) The method of claim 17, wherein the [[agent]] angiogenic factor is selected from FGF-1, FGF-2, FGF-4, and FGF-5.

31. (Currently Amended) The method of claim 17, wherein the [[agent]] angiogenic factor is selected from inducible NOS and endothelial NOS.

32. (Currently Amended) The method of claim 17, wherein the [[agent]] angiogenic factor is PR39.

33. (Cancelled)

34. (Previously Presented) The method of claim 17, wherein the method enhances collateral blood vessel formation in the heart or leg muscle tissue.

Claims 35 – 38 (Cancelled)

39. (Currently Amended) A therapeutic composition comprising early attaching cells obtained from bone marrow, which cells have been transfected with an adenoviral vector comprising at least one polynucleotide that encodes one or more [[agents]] angiogenic factors selected from hypoxia inducing factor-1 (HIF-1), endothelial PAS domain protein 1 (EPAS1), Monocyte

Chemoattractant Protein 1 (MCP-1), granulocyte-monocyte colony stimulatory factor (GM-CSF), PR39, a fibroblast growth factor (FGF), and a nitric oxide synthase (NOS).

40. (Currently Amended) The composition of claim 39, further comprising conditioned medium containing one or more of the [[agents]] angiogenic factors expressed from the polynucleotides.
41. (Original) The composition of claim 39, wherein the polynucleotide further comprises a transcription regulatory region operatively associated with the polynucleotide.
42. (Currently Amended) The composition of claim 39, wherein the transfected cells have been stimulated in vitro by exposure to hypoxia.
43. (Previously Presented) The composition of claim 39, further comprising an anticoagulant.
44. (Cancelled)
45. (Currently Amended) The composition of claim 39, wherein the early attaching cells [[are]] consist essentially of marrow-derived stromal cells.
46. (Original) The composition of claim 39, wherein the composition is intended to be injected into a patient having ischemic tissue and the early attaching cells are derived from bone marrow obtained from the patient.
47. (Currently Amended) The method of claim 17, further comprising, prior to the injecting, culturing the early attaching cells in a culture medium to produce conditioned medium containing one or more of the [[agents]] angiogenic factors expressed from the polynucleotides, and wherein

In re Application of:
Epstein et al.
Application No.: 10/618,183
Filed: July 10, 2003
Page 5

PATENT
Attorney Docket No.: MEDIV2010-4

the method further comprises injecting a composition comprising the one or more [[agents]]
angiogenic factors in the conditioned medium along with the transfected early attaching cells.[[.]]

48. (Previously Presented) The method of claim 17, wherein the injecting is at multiple sites in the muscle tissue.

49. (Currently Amended) The method of claim[[48]] 47, wherein the effective amount is about 0.2 to about 0.5 ml of the composition in each of from about 12 to about 25 sites.